New treatment shown to reduce recurrence of debilitating diarrhea

Jan 20, 2010

A combination of two fully human monoclonal antibodies developed by MassBiologics (MBL) of the University of Massachusetts Medical School (UMMS) and Medarex, a wholly owned subsidiary of Bristol-Myers Squibb Co. (NYSE:BMY), when given with standard antibiotics, was shown to reduce recurrence of a debilitating form of diarrhea by 72 percent in patients enrolled in a Phase 2 clinical trial. The results of the trial are reported in the article "Treatment with Monoclonal Antibodies against Clostridium difficile Toxins" to be published January 21, 2010 in the New England Journal of Medicine (NEJM).

"We are pleased that this new treatment had such a significant impact for these patients," said Donna Ambrosino, MD, executive director of MassBiologics, professor of pediatrics at UMMS and senior author of the NEJM paper. "This disease is a growing public health problem and the need for effective treatment options is quite clear. The team at MBL is gratified that we have been able to discover effective , and then translate the discovery to a product with the collaboration of our colleagues at Medarex."

difficile (C. difficile) is a common bacterium that can colonize the human gastrointestinal tract. C. difficile can cause disease when patients are treated with antibiotics for other infections and C. difficile then grows unchecked in the gastrointestinal tract, producing large amounts of two toxins, commonly called toxin A and toxin B. The toxins can cause severe diarrhea and damage the lining of the large intestine. The incidence of C. difficile infection (CDI) in the United States is rapidly increasing, with rates doubling from 2000 to 2005.

C. difficile infects more than 300,000 people each year in the United States and is most common among hospitalized patients and residents of long-term care facilities. Furthermore, the emergence of an epidemic strain of C. difficile has been implicated in severe outbreaks of CDI in the United States, Canada and the United Kingdom, and has affected otherwise healthy individuals in the community. The virulence of the epidemic strain has been attributed, at least in part, to the bacteria's markedly increased efficiency in producing both toxins A and B. The epidemic strain appears to cause both more severe illness initially, and a subsequently higher rate of relapse.

To combat this emerging public health problem, researchers at MassBiologics and Medarex worked to develop fully human antibodies that could neutralize both toxins generated by C. difficile. In the current study reported in the NEJM, 200 patients with CDI were enrolled in a randomized, double-blind, placebo-controlled Phase 2 trial. The trial was conducted at 30 locations in the United States and Canada from July 2006 through April of 2008. Patients were divided into two groups and received either a single injection of the two antibodies, or a placebo, in addition to the standard of care antibiotic treatments for CDI. The patients were followed for 84 days to see how many would suffer a recurrence of the disease.

The results showed only 7 percent of those patients who received the antibodies suffered a recurrence, while 25 percent of those who received the placebo had a recurrence—a 72 percent reduction in recurrence. Of the 44 patients infected with the epidemic strain of C. difficile, only 8 percent who received the antibodies suffered a recurrence compared with 32 percent of those who received the placebo. "The trial results are impressive," Lorraine Kyne, MD, MPH, wrote in an NEJM editorial accompanying the paper's publication. "This novel nonantibiotic approach to secondary prevention is likely to offer hope to physicians and patients battling C. difficile infection."

The bench-side research program to develop a new treatment for CDI began at MBL in 2002. The program advanced to a Phase 1 clinical trial with both antibodies in 2006, then the Phase 2 study that is the subject of the current NEJM article. "This has been an intensive program, involving many talented and devoted people, both here at MBL and at Medarex" said Dr. Ambrosino. "It's been a pleasure to work with such an outstanding team."

The rights to commercialize the two new antibodies against C. difficile toxins have been licensed to Merck & Co.

Explore further: Research shows that bacteria survive longer in contact lens cleaning solution than thought

add to favorites email to friend print save as pdf

Related Stories

The balance shifts

May 27, 2008

The risk of contracting a Clostridium difficile infection following operations for which a "prophylactic" antibiotic is given to prevent infection is 21 times greater now than it was just a decade ago, according to researchers ...

Doctors identify patients at high risk of C. difficile

Apr 01, 2009

Doctors have developed and validated a clinical prediction rule for recurrent Clostridium difficile (C. difficile) infection that was simple, reliable and accurate, and can be used to identify high-risk patients most likely t ...

C. difficile and antibiotics not necessarily linked

Oct 07, 2008

The latest study by Dr. Sandra Dial from the Research Institute of the MUHC, McGill University, and Attending Staff in the Intensive Care Unit at the Jewish General Hospital, questions the assumption held by a vast majority ...

Diarrhea germ may be more widespread

Dec 02, 2005

A diarrhea-causing germ that once contained in hospital patients has become widespread in the United States -- sometimes fatal, health officials said.

Recommended for you

Ebola virus in Africa outbreak is a new strain

9 hours ago

The Ebola virus that has killed scores of people in Guinea this year is a new strain—evidence that the disease did not spread there from outbreaks in some other African nations, scientists report.

Researchers see hospitalization records as additional tool

9 hours ago

Comparing hospitalization records with data reported to local boards of health presents a more accurate way to monitor how well communities track disease outbreaks, according to a paper published April 16 in the journal PLOS ON ...

User comments : 0

More news stories

Down's chromosome cause genome-wide disruption

The extra copy of Chromosome 21 that causes Down's syndrome throws a spanner into the workings of all the other chromosomes as well, said a study published Wednesday that surprised its authors.

Simplicity is key to co-operative robots

A way of making hundreds—or even thousands—of tiny robots cluster to carry out tasks without using any memory or processing power has been developed by engineers at the University of Sheffield, UK.

Progress in the fight against quantum dissipation

(Phys.org) —Scientists at Yale have confirmed a 50-year-old, previously untested theoretical prediction in physics and improved the energy storage time of a quantum switch by several orders of magnitude. ...